Pharmaceuticals News and Research

RSS

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

Technological breakthroughs, national immunization programs and emerging vaccines for treating, rather than preventing, disease are priming the global vaccine market for growth.

6 Oct 2009

SEC completes investigation of PharmaNet Development, no action recommended

PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.

6 Oct 2009

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd., a privately held UK company.

6 Oct 2009

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today awarded Dr. Mari Hashitate Dallas of St. Jude Children’s Research Hospital in Memphis, Tenn., the Millipore Guava® Flow Cytometry Award.

6 Oct 2009

Government of Alberta reimburses first medication to improve vision and restore quality of life

Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.

6 Oct 2009

Tianyin Pharmaceutical declares quarterly cash dividend to common stock shareholders

Tianyin Pharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today declared a quarterly cash dividend to be paid to its common stock shareholders.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Grifols International chosen as Health Robotics' exclusive CytoCare partner in Latin America

Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Grifols International S.A. for its revolutionary CytoCare Robot.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009.

6 Oct 2009

Otsuka Pharmaceutical provided access to BioWa's POTELLIGENT Technology platform

BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).

6 Oct 2009

Kevetrin reduces tumor volume by 72%: Cellceutix

October is breast cancer awareness month with many supporters touting pink ribbons, but in health stocks investors are watching the market closely for news of new drugs in various stages of testing. Recently, Cellceutix announced its pharmaceutical compound Kevetrin reduced tumor volume by 72%, giving new hope for breast cancer patients.

6 Oct 2009

U.N. officials highlight need for vaccine assistance to poor countries

U.N. officials on Sunday said that the H1N1 (swine flu) virus had arrived in poorer countries, highlighting a growing need for financial assistance and H1N1 vaccines for such regions, SAPA/News24.com reports.

6 Oct 2009

UTEK launches new online IP licensing platform for health-care devices

UTEK Corporation (NYSE Amex:UTK), a global IP licensing and innovation services company, is pleased to announce the launch of its new online IP licensing platform for health-care devices: www.MedicalDeviceLicensing.com.

5 Oct 2009

MSF calls on drug companies to pool HIV patents

Medecins Sans Frontieres (MSF) recently launched an e-mail campaign calling on nine of the world's largest pharmaceutical companies to "release their patents on specific HIV drugs into a collective pool that will increase access and affordability to treatment in developing countries," Inter Press Service reports (Borde, 10/1).

5 Oct 2009

Eleventh-hour lobbying campaigns hope to lower costs to industry

As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.

5 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

Bausch & Lomb announces acquisition of Tubilux Pharma's commercial assets

Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

5 Oct 2009

Pharmaceuticals News and Research

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

SEC completes investigation of PharmaNet Development, no action recommended

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

Government of Alberta reimburses first medication to improve vision and restore quality of life

Tianyin Pharmaceutical declares quarterly cash dividend to common stock shareholders

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Grifols International chosen as Health Robotics' exclusive CytoCare partner in Latin America

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Otsuka Pharmaceutical provided access to BioWa's POTELLIGENT Technology platform

Kevetrin reduces tumor volume by 72%: Cellceutix

U.N. officials highlight need for vaccine assistance to poor countries

UTEK launches new online IP licensing platform for health-care devices

MSF calls on drug companies to pool HIV patents

Eleventh-hour lobbying campaigns hope to lower costs to industry

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

Bausch & Lomb announces acquisition of Tubilux Pharma's commercial assets

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring